| 1 |
35313299 | MiR-199a-3p Overexpression Suppressed Cell Proliferation and Sensitized Chronic Myeloid Leukaemia Cells to Imatinib by Inhibiting mTOR Signalling. | 2022 Mar 21 |
4 |
| 2 |
35597499 | A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity. | 2022 Jun 15 |
1 |
| 3 |
33603171 | Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. | 2021 Mar |
1 |
| 4 |
34893099 | [Transcriptome Analysis of Chronic Myelogenous Leukemia Cell Line with Imatinib Resistance]. | 2021 Dec |
1 |
| 5 |
33022360 | Imatinib exhibit synergistic pleiotropy in the prevention of colorectal cancer by suppressing proinflammatory, cell survival and angiogenic signaling. | 2020 Dec |
1 |
| 6 |
28777148 | New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs. | 2019 Jan |
2 |
| 7 |
29423045 | Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. | 2018 Jan 9 |
1 |
| 8 |
29552859 | [Inhibitory effect and mechanism of platycodin D combined with imatinib on K562/R]. | 2018 Jan |
1 |
| 9 |
28442505 | Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib. | 2017 Aug 15 |
1 |
| 10 |
28612529 | [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph +ALL Cell Line]. | 2017 Mar |
1 |
| 11 |
28711648 | Alteration of PDGFRβ-Akt-mTOR pathway signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. | 2017 Sep |
1 |
| 12 |
28962554 | Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression. | 2017 Sep 29 |
2 |
| 13 |
29046392 | Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. | 2017 Dec 6 |
1 |
| 14 |
26892093 | Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells. | 2016 Apr |
1 |
| 15 |
26898422 | Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway. | 2016 Mar |
1 |
| 16 |
26919095 | Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. | 2016 Apr 5 |
1 |
| 17 |
25757539 | PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). | 2015 Apr |
8 |
| 18 |
25979368 | Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. | 2015 Aug |
3 |
| 19 |
26617858 | Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines. | 2015 |
1 |
| 20 |
24112092 | Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. | 2014 Feb |
1 |
| 21 |
24691473 | Translational regulation of GPx-1 and GPx-4 by the mTOR pathway. | 2014 |
1 |
| 22 |
25375091 | MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. | 2014 Nov 30 |
2 |
| 23 |
23395818 | Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia. | 2013 May |
2 |
| 24 |
24260131 | Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells. | 2013 |
1 |
| 25 |
21993902 | Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. | 2012 Feb |
1 |
| 26 |
22895079 | Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. | 2012 Nov |
4 |
| 27 |
21299849 | BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. | 2011 Feb 7 |
1 |
| 28 |
21392556 | Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. | 2011 Jun |
2 |
| 29 |
21715304 | BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. | 2011 Sep 8 |
1 |
| 30 |
19643477 | mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. | 2010 May |
1 |
| 31 |
19846571 | Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. | 2010 Jan |
1 |
| 32 |
20499309 | [Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor]. | 2010 May |
1 |
| 33 |
18783828 | Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. | 2009 Mar |
2 |
| 34 |
18223253 | Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. | 2008 Mar 28 |
1 |
| 35 |
16740780 | Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. | 2006 Jun 1 |
1 |
| 36 |
16908864 | Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. | 2006 Aug 22 |
2 |
| 37 |
15790787 | Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. | 2005 Oct 1 |
3 |
| 38 |
16136169 | Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. | 2005 Oct |
1 |
| 39 |
14522890 | Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. | 2003 Sep 15 |
2 |